Aptevo Therapeutics Inc. (APVO): Insider Trading, Congress Trades & Research | Tormere

APVO

$1.37+0.74%visit website

Aptevo Therapeutics Inc.

Market Cap

$2M

Live price × SEC shares (Aug 14, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

2.55

42mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

0.4

Mkt cap / shareholders' equity

Flagged input, hover for details

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	4,044	3,535	3,924	3,696	15,199
Operating income	(7,610)	(5,996)	(6,837)	(6,443)	(26,886)
Net income	(7,549)	(5,806)	(6,697)	(6,356)	(26,408)
EPS (basic) ($)	(2.23)		(6.41)	(5.31)	—
EPS (diluted) ($)	(2.23)		(6.41)	(5.31)	—
Weighted avg. shares (basic)	4,049		1,061	1,196
Weighted avg. shares (diluted)	4,049		1,061	1,196

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 42 more quarters, back to Mar 2015, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

Up to $2.31M in stock may be sold through Roth by Aptevo Therapeutics (APVO).

Stock Titan · 2026-10-30

APVO: Mipletamig Combination Therapy Leads to 21% Stem Cell Transplantation Rate

Yahoo · 2026-10-27

Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

Yahoo · 2026-10-26

Aptevo Reports 10 AML Patients Advanced To Stem Cell Transplant Following Treatment With Mipletamig In Combination With Venetoclax And Azacitidine

Benzinga · 2026-10-26

10 of 47 newly diagnosed blood cancer patients reached a donor stem cell transplant. It may offer a chance of cure.

Stock Titan · 2026-10-26

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

Yahoo · 2026-10-14

Aptevo Therapeutics (APVO) Slips to $1.79 as Shares Test Lower End of Recent Range - Total Put Call

https://www.siam.in/ · 2026-10-10

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Yahoo Finance · 2026-09-24

Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML

Yahoo Finance · 2026-09-03

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Yahoo Finance · 2026-09-03

APVO: Focusing on Three Key Areas of Development

Yahoo Finance · 2026-08-24

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Yahoo Finance · 2026-08-14

APVO Forecast — Price Target — Prediction for 2027

TradingView · 2026-06-25

Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Yahoo Finance · 2025-11-19

symbol__ Stock Quote Price and Forecast

CNN · 2024-03-09

Informational purposes only, not investment advice.

Corporate Events (8-K)

2 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Nov 2, 2026 accepted 6:25 PM ET	8.01Other events	Document SEC ↗
Oct 26, 2026 accepted 8:13 AM ET	8.01Other events	Document SEC ↗